Drug Testing: Technologies and Global Markets
August 05, 2008
Wellesley, Mass—According to a new technical market research report, DRUG TESTING: TECHNOLOGIES AND GLOBAL MARKETS (PHM013E) from BCC Research (www.bccresearch.com), the global drugs of abuse (DOA) testing market generated $1.9 billion in 2007. This is expected to increase to $2.0 billion in 2008 and $2.6 billion in 2014, for a compound annual growth rate (CAGR) of 4.6%.
The market is divided by region into the United States, the European Union and the rest of the world. The U.S. segment is the largest, worth $1.4 billion in 2007 and an estimated $1.5 billion in 2008. This should grow at a CAGR of 5.2% to reach $2.0 billion in 2014.
The European Union is the second largest segment, worth $365.2 million in 2007. This should increase to $374.2 million in 2008 and $445.9 million in 2014, for a CAGR of 2.9%.
The rest of the world is the smallest market segment, generating $123.8 million in 2007 and an estimated $123.8 million in 2008. This segment is expected to reach $135.3 million in 2014, a CAGR of 1.3%.
DOA testing has evolved from a small number of companies that focused on substance abuse testing of their employees during the 1980s to a multi-billion dollar industry. The market shows strong growth, driven by legislation requirements in key markets. Emerging industry segments within the market include home drug testing and school drug testing that are being driven by technology and policy developments.
Technology advancements in the diagnostics sector as well as the entry of new companies in the diagnostics industry have transformed the market. Consolidation trends in the in vitro diagnostics sector also have influenced the drug testing market.
Currently, the drug testing market is dominated by various immunoassays based on the antibody–antigen interaction principles, which involves the drug in question, a competing drug and some type of detection system. These tests are generally used in conjunction with more sensitive tests such as gas chromatography/ mass spectrometry.
Drug Testing: Technologies and Global Markets( PHM013E )
Publish Date: Jul 2008
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.
BCC Library Membership Benefits
Unlimited Access to Market Research Reports for Academic Institutions and Corporations.
Custom Research
Tailored solutions across industries for your unique business needs.
More in Pharmaceuticals
- Global Bispecific Antibodies Market to Reach $22.3 Billion by 2030 as Immuno-Oncology Innovation and R&D Investment Accelerate
- Neuroprotective Agents Market to Reach $60.9 Billion by 2030 as Neurological Disease Burden and Aging Populations Drive Pharmaceutical Investment
- Radioligand Therapeutics Market to More Than Double to $4.8 Billion by 2030 as Targeted Cancer Treatments Gain Regulatory Momentum
- Global GLP-1 Analogues Market to Reach $268.4 Billion by 2030
- AI in Clinical Trials Poised for Rapid Growth with a 22.6% CAGR Forecast
Reports from Pharmaceuticals
Recent News
- Biometrics as a Service in Medical Devices to Reach $2.7 Billion by 2030, Driven by Remote Patient Monitoring Demand
- Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment
- AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment
- Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology
- Cloud Computing in Cell Biology, Genomics and Drug Development to Reach $15.6 Billion by 2030 as Biological Data Explosion Drives Demand